AGP Picks
View all

Science Press Releases
Provided by AGP

Science Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

Press releases published on May 15, 2026

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
May 15, 2026

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

Indeterminate GlobeNewswire
ESET’s Chief Security Evangelist Tony Anscombe to Co-Chair NetDiligence Cyber Risk Summit
May 15, 2026

ESET’s Chief Security Evangelist Tony Anscombe to Co-Chair NetDiligence Cyber Risk Summit

Indeterminate GlobeNewswire
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
May 15, 2026

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

Indeterminate GlobeNewswire
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
May 15, 2026

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 15, 2026

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

Indeterminate GlobeNewswire
Bond Provides Business Update and Reports 2026 First Quarter Financial Results
May 15, 2026

Bond Provides Business Update and Reports 2026 First Quarter Financial Results

Indeterminate GlobeNewswire
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
May 15, 2026

BioCardia Reports First Quarter 2026 Business Highlights and Financial Results

Indeterminate GlobeNewswire
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
May 15, 2026

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

Indeterminate GlobeNewswire
GT Biopharma Reports First Quarter 2026 Financial Results
May 15, 2026

GT Biopharma Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire
ELECTRA AI and Iron Horse Acquisition II Corp. (Nasdaq: IRHO) Announce Filing of Registration Statement on Form S-4 with the SEC in Connection with their Proposed Business Combination
May 15, 2026

ELECTRA AI and Iron Horse Acquisition II Corp. (Nasdaq: IRHO) Announce Filing of Registration Statement on Form S-4 with the SEC in Connection with their Proposed Business Combination

Indeterminate GlobeNewswire
Xpanner Secures $18 Million Series B Bridge Round to Scale AI-Powered Automation in Construction
May 15, 2026

Xpanner Secures $18 Million Series B Bridge Round to Scale AI-Powered Automation in Construction

Indeterminate GlobeNewswire
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Indeterminate GlobeNewswire
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
May 15, 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

Indeterminate GlobeNewswire
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
May 15, 2026

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

Indeterminate GlobeNewswire
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
May 15, 2026

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Profusa Announces Listing Transfer to The Nasdaq Capital Market
May 15, 2026

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Indeterminate GlobeNewswire
JOYY to Announce First Quarter 2026 Financial Results on May 25, 2026
May 15, 2026

JOYY to Announce First Quarter 2026 Financial Results on May 25, 2026

Indeterminate GlobeNewswire
Intercontinental ICU Air Ambulance Transport Highlights Growing Need for Continuous In-Flight Medical Care
May 15, 2026

Intercontinental ICU Air Ambulance Transport Highlights Growing Need for Continuous In-Flight Medical Care

Indeterminate GlobeNewswire
Davos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and Care
May 15, 2026

Davos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and Care

Indeterminate GlobeNewswire
Quantum Cyber Launches quantum-cyber.ai Targeting Homeland Security, Autonomous Drone, and Quantum Technology Sectors
May 15, 2026

Quantum Cyber Launches quantum-cyber.ai Targeting Homeland Security, Autonomous Drone, and Quantum Technology Sectors

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Science Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.